Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Asymmetric who wrote (687)	3/24/1999 3:17:00 AM
From: scaram(o)uche	Read Replies (2) of 2001

from the properdin release...... ''With the recent commercialization of our ADCON® technology, we have focused on pipeline positioning and felt it was time to advance this promising program with significant clinical and commercial potential,'' said Thomas O. Oesterling, President and Chief Executive Officer of Gliatech Inc. ''We have many exciting exploratory projects and will continually assess their market and clinical potential to ensure a rich commercial pipeline.'' As NXTR looked at GILD, I hope that GLIA is looking at several potential partners. Oesterling et al. have put GLIA into this position...... a company that (1) turned a profit last quarter on product revenues, penetrating rapidly into approximately 15% of the estimated market, (2) has Adcon-P in pivotal trials, and (3) has a variety of additional projects, targeting attractive and unmet markets, moving through development or the clinic. There are several contributors to SI that could be considered expert at picking complementary projects at big-cash, big-science companies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next